Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
Chris Labaki(Beth Israel Deaconess Medical Center), Toni K. Choueiri(Harvard University), Naveen S. Basappa, Ziad Bakouny(Dana-Farber Cancer Institute), J. Connor Wells(Queen's University), Georges Gebrael(University of Utah), Renée Maria Saliby(Yale University), Rana R. McKay(University of California San Diego), Luís Meza(City of Hope), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), Elizabeth P. Henske(Brigham and Women's Hospital), David A. Braun(Yale Cancer Center), Sumanta Pal(City of Hope), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Neeraj Agarwal(University of Utah), Daniel Yick Chin Heng(University of Calgary), Camillo Porta(University of Pavia)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k